Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2005;331:1034-1035 (5 November), doi:10.1136/bmj.331.7524.1034
Should be much more accessible and patient centred
| The first 150 words of the full text of this article appear below. |
The traditional model for communicating with patients about their medicines is that doctors decide the best treatment and patients follow their doctors' instructions with only limited independent access to information about treatment. The Association of the British Pharmaceutical Industry (ABPI) is now reviewing its code of practice,1 and this is an important opportunity to move to a more modern view of patientsas partners of health professionals and decision makers in relation to their health. The main aim of the code is to protect patients from potentially harmful influence. It currently focuses heavily on regulating the pharmaceutical industry's communications with health professionals and imposes highly restrictive conditions on direct communication with patients. This model is seriously flawed.
The ABPI code of practice should reflect the increasing role that patients are taking in decisions about their health and treatment, as well as patients' entitlement to access information from any source they
Joanne M Shaw, director
(jshaw@medicines-partnership.org)
Medicines Partnership, London SE1 7JN
Geraldine Mynors, head of projects, Caroline Kelham, project manager
Medicines Partnership, London SE1 7JN
Read all Rapid Responses